Recombinant Mouse TGFBR1 (C-Fc)

Description

EnkiLife provides the Recombinant Mouse TGFBR1 (C-Fc) protein,aslo know as AAT5,activin A receptor type II-like kinase, 53kD,ACVRLK4,ALK-5,ALK-5ALK5,LDS1A,LDS2A,SKR4,tbetaR-I,TGFB1R1,TGF-beta receptor type I,TGFbetaRI,TGFBR1,TGF-bRI,TGFR-1, which features high purity, high activity, and high stability. It can be applied in scientific research, biopharmaceuticals, and other fields.Purity:Greater than 95% as determined by reducing SDS-PAGE;Endotoxin Level:<1 EU/µg as determined by LAL test.;Construction:Recombinant Mouse TGF-beta Receptor Type-1 is produced by our Mammalian expression system and the target gene encoding Leu30-Glu125 is expressed with a human IgG1 Fc tag at the C-terminus.Accession:Q64729. Expression Host:Human Cells.Species:Mouse.Predicted Molecular Mass:37.6 KDa. Background:TGF-beta RI, also called ALK-5, is an approximately 55 kDa type I transmembrane serine/threonine receptor kinase. In the presence of TGF-beta, TGF-beta RI forms a complex with, and is phosphorylated by, TGF-beta RII. Phosphorylated TGF-beta RI can then transiently bind and phosphorylate Smad2 and Smad3. TGF-beta functions as a tumor suppressor by inhibiting the cell cycle in the G1 phase. Administration of TGF-beta is able to protect against mammary tumor development in transgenic mouse models in vivo. Disruption of the TGF-beta/SMAD pathway has been implicated in a variety of human cancers, with the majority of colon and gastric cancers being caused by an inactivating mutation of TGF-beta RII. TGF-beta RI is likely important during development, since mice deficient for TGF-beta RI die at midgestation with severe defects in vascular development of the yolk sac and placenta, and an absence of circulating red blood cells. Furthermore, TGF-beta RI appears to be involved in proper lymphatic network development.